Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of fecal bacteria transplantation on immunotherapy for advanced colorectal cancer: A single-center, prospective, randomized controlled study

ABSTRACT: Interventions: experimental group:Fecal bacteria transplantation + immunotherapy;control group:Immunotherapy only Primary outcome(s): Objective response rate;Progression-free survival;Overall survival Study Design: Parallel

DISEASE(S): Advanced Colorectal Cancer

PROVIDER: 2741229 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Oncolytic biomineralized bacteria for tumor immunotherapy

Project description:Bacteria-based cancer immunotherapy, dated back to Coley’s toxins (inactivated bacteria) in 1893, has recently regained substantial attentions, usually by using attenuated bacteria to transform immune-silent “cold” tumors into immune-inflamed “hot” ones. However, while inactivated bacteria showed limited antitumor efficacy, attenuated live bacteria often possessed significant safety risks. Herein, by biomineralizing growth of manganese dioxide on the surface of paraformaldehyde-fixed gram-negative Salmonella typhimurium (S. typhimurium), we obtained MnO2-coated fixed S. typhimurium (M@F.S), which showed potent immune-stimulating effects via activating multiple pathways including Toll-like receptors (TLRs), cyclic GMP-AMP Synthase (cGAS)-stimulator of interferon genes (STING) and nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs). Single intratumoral administration of M@F.S at safe doses resulted in surprisingly strong efficacies in suppressing various types of mouse tumor models and a rabbit cancer model, and the cured mice and rabbits gained immune memory to reject re-challenged tumors. An abscopal antitumor effect was also observed, suggesting systemic antitumor immunity triggered by local injection of M@F.S. The antitumor mechanisms of M@F.S were preliminarily demonstrated to be innate immune activation initiated by multiple signaling pathways, followed by subsequent activation of tumor-specific immune responses, together with the modulation of immunosuppressive tumor microenvironment. We further demonstrated the efficacy of biomineralized bacteria in inhibiting an orthotopic breast tumor model established on tree shrews, an alternative animal model to primates with better clinical relevance. Such oncolytic biomineralized bacteria could be a potent yet safe immunotherapeutic agent for treatment of various solid tumors.

2024-08-01 | GSE211069 | GEO

Oncolytic biomineralized bacteria for tumor immunotherapy

Project description:Oncolytic biomineralized bacteria for tumor immunotherapy

| PRJNA868767 | ENA

Cancer Immunotherapy: Fecal Microbiota Transplantation Brings Light.

Project description:Immunotherapy is revolutionizing tumor treatment by activating the immune response to tumors. Among them, immunotherapy represented by immune checkpoint inhibitors is considered to be a milestone in tumor treatment. It has revolutionized the management of advanced malignant tumors by activating T cells, promoting cytotoxic signaling pathways, and killing tumor cells, effectively improving the overall survival of patients. However, resistance to immunotherapy and immune-related adverse events remain challenges for immunotherapy. It has been demonstrated in previous studies that modulating intestinal microbiota can enhance immunotherapy response and reduce complications. Currently, the more mature method for microbiota regulation is fecal microbiota transplantation, which involves transfering a donor's microbiome to the recipient in the form of capsules or fecal microbiota suspension to restore the richness of the recipient's intestinal microbiota. In terms of cancer immunotherapy, fecal microbiota transplantation in patients who fail to respond to immune checkpoint inhibitors is expected to produce better prognosis for patients.

| S-EPMC9589549 | biostudies-literature

Fecal bacteria

Project description:Fecal bacteria Genome sequencing and assembly

| PRJNA874082 | ENA

Fecal Microbiota Transplantation for Metabolic Syndrome

Project description:Fecal Microbiota Transplantation for Metabolic Syndrome

| PRJEB46778 | ENA

Fecal Microbiota Transplantation for Ulcerative Colitis.

Project description:Fecal Microbiota Transplantation for Ulcerative Colitis.

| PRJEB46777 | ENA

Eubacterium rectale improves the efficacy of anti-PD1 immunotherapy in melanoma via L-serine-mediated NK-cell activation

Project description:NK cells, as a type of key immune cell, play essential roles in tumor cell immune escape and immunotherapy. Accumulating evidence has demonstrated that the gut microbiota community affects the efficacy of anti-PD1 immunotherapy and that remodeling the gut microbiota structure is a promising strategy to enhance anti-PD1 immunotherapy responsiveness in advanced melanoma patients; however, the details of the mechanism remain elusive. In this study, we found that Eubacterium rectale (E. rectale) was significantly enriched in melanoma patients who responded to anti-PD1 immunotherapy and a high E. rectale abundance was related to longer survival in melanoma patients. Furthermore, administration of E. rectale remarkably improved the efficacy of anti-PD1 therapy and benefited the overall survival of tumor-bearing mice; moreover, application of E. rectale significantly recruited NK cells into the tumor microenvironment. Interestingly, conditioned medium isolated from an E. rectale culture system dramatically enhanced NK-cell function. Through GC-MS/ UHPLC-MS/MS-based metabolomic analysis, L-serine production was found to be significantly decreased in the E. rectale group; moreover, administration of an L-serine synthesis inhibitor dramatically increased NK-cell activation, which led to enhanced anti-PD1 immunotherapy effects. Mechanistically, supplementation with L-serine or application of the L-serine synthesis inhibitor affected NK-cell activation through Fos/Fosl. In summary, our findings reveal the role of bacteria-modulated serine metabolic signaling in NK-cell activation and provide a novel therapeutic strategy to improve the efficacy of anti-PD1 immunotherapy in melanoma.

2023-04-14 | GSE225920 | GEO

Oleanolic acid inhibits the development of breast cancer by regulating lactic acid bacteria and the Cytokinecytokine receptor interaction pathway

Project description:It was found that after OA treatment, compared with the CK group, the abundance of lactic acid bacteria in the intestinal flora of mice in the OA group increased, and the increase in the abundance of lactic acid bacteria made the gene Il10 upregulated, Il10 had a significant effect on tumor volume reduction and prolongation of mouse survival, and played a role through cytokine receptor interaction pathway.

2024-03-13 | GSE231570 | GEO

Fecal microbiota transplantation: no longer cinderella in tumour immunotherapy.

Project description:The incidence of cancer has shown a great increase during the past decades and poses tough challenges to cancer treatment. Anti-tumour immunotherapy, represented by immune checkpoint inhibitors (ICIs), possesses favorable remission in unrestricted spectrum of cancer types. However, its efficacy seems to be heterogeneous among accumulating studies. Emerging evidences suggest that gut microbiota can modulate anti-tumour immuno-response and predict clinical prognosis. Therefore, remodeling microbiota characteristics with fecal microbiota transplantation (FMT) may be capable of reinforcing host ICIs performance by regulating immune-tumour cell interactions and altering microbial metabolites, thereby imperceptibly shifting the tumour microenvironment. However, the long-term safety of FMT is under concern, which calls for more rigorous screening. In this review, we examine current experimental and clinical evidences supporting the FMT efficacy in boosting anti-tumour immuno-response and lessening tumour-related complications. Moreover, we discuss the challenges in FMT and propose feasible resolutions, which may offer crucial guidance for future clinical operations.

| S-EPMC10831174 | biostudies-literature

Fecal microbiota transplantation treatment maintains post antibiotics gut function by change the gut microbiome and fecal metabolome to reduce gut inflammation and oxidative stress in nile tilapia (Oreochromis niloticus)

Project description:The imbalance of intestinal flora can affect the immune function and structural integrity of the intestinal barrier, leading to the colonization and reproduction of opportunistic pathogenic bacteria in the intestine to become the dominant flora, eventually inducing enteritis. This study aimed to investigate whether fecal microbiota transplantation (FMT) could improve the gut barrier in Nile tilapia (Oreochromis niloticus). The experiment involved administering normal saline (NS group) and fecal microbiota (FMT group) (from the negative control group (C group)) to tilapia that had been treated with oxytetracycline hydrochloride (OTC) (M group) by gavage. A total of 300 male tilapia (mean body weight 596.65 ± 47.18 g) were used, with 180 of them being fed OTC (120 mg/kg body weight/day) for 7 days to induce intestinal oxidative stress, while the rest served as the control group. After confirmation of mild chronic enteritis, the tilapia were treated in different ways.

2024-03-26 | MTBLS9451 | MetaboLights

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data